OpenBit ResearchOpenBit
中文

What's driving uniQure NV (QURE)

Compiled from the engine's research, source claims and public filings in this dossier. Each has its own data date, listed below.

Research summary

Does QURE’s high-dose treatment durably slow disease progression?

Why it matters now

The treatment-efficacy evidence can affect QURE’s valuation through the durability and credibility of its clinical development outcome.

Next checkpoint

QURE earnings (expected 2026-11-09)

This checkpoint sits on a shared driver. The engine does not explain how it carries over to QURE, so treat it as context, not a verified checkpoint for this company.

What would break the thesis

Longer follow-up or a better-controlled analysis fails to show a treatment-related slowing of progression.

Research drivers

  • Does QURE’s high-dose treatment durably slow disease progression?

    Bullish · Emerging · Updated

    The supplied analyses support a durable slowing signal, while the 48-month cUHDRS result is weaker and the company identifies missing data and survivor bias as limitations.

Source claims

Source labels are as recorded in our data. The dossier does not include links to the originals, so these are not verified quotations.

  • uniQure reported that updated data from all 15 high-dose patients showed 80% slowing of disease progression based on cUHDRS at 36 months, with nominal p=0.005.

    Relayed by: Benzinga · Event date on record:

  • uniQure reported that, among 12 high-dose patients at 48 months, TFC showed 61% slowing of disease progression, with nominal p=0.008.

    Relayed by: Benzinga · Event date on record:

  • uniQure stated that treatment effect at 48 months was likely understated by substantial missing data and survivor bias in the updated external control.

    Relayed by: Benzinga · Event date on record:

  • In a post hoc analysis using the prior external control, uniQure reported 54% slowing of disease progression on cUHDRS at 48 months, with nominal p=0.041.

    Relayed by: Benzinga · Event date on record:

  • uniQure reported that updated data from all 15 high-dose patients showed 67% slowing of disease progression based on TFC at 36 months, with nominal p=0.011.

    Relayed by: Benzinga · Event date on record:

Related sectors

Biotech

Filed holders

This dossier has no filed holders to show. That does not mean no institution holds it.